The person depicted is a model used for illustrative purposes only.
MENVEO is the only MenACWY vaccine approved for use in infants as young as 2 months of age1
Most infants and toddlers who completed the 4-dose series had a protective immune response with MENVEO1
BACTERICIDAL ANTIBODY RESPONSE RATES POST-DOSE 3 AND POST-DOSE 4 IN CHILDREN 2 MONTHS THROUGH 23 MONTHS OF AGE1,*
MENVEO demonstrated higher geometric mean titers (GMTs) post-dose 4 in infants and toddlers1
GMTs are a measure of the level of immune response to a vaccine in a specific study group. Infants and toddlers vaccinated with MENVEO were found to have circulating bactericidal antibodies to MenACWY following the full 4-dose series.
GMTs POST-DOSE 3 AND POST-DOSE 4 IN CHILDREN 2 MONTHS THROUGH 23 MONTHS OF AGE1,†
GMT=geometric mean titers; hSBA=serum bactericidal assay with exogenous human complement source.
|*||Prespecified criteria for adequacy of immune response were met (LL of the 95% CI >80% for serogroup A and >85% for serogroups C, W, and Y).|
|†||hSBA GMTs at 1-month post-dose 3 and 1-month post-dose 4 of MENVEO with routine infant/toddler vaccines.|
Randomized, controlled, multicenter study of infants initiating vaccination at 2 months of age with either MENVEO concomitantly with routine infant vaccines (diphtheria toxoid, tetanus toxoid, and acellular pertussis [DTaP], inactivated poliovirus [IPV] types 1, 2, and 3, hepatitis B, Haemophilus influenzae type b [Hib], pentavalent rotavirus, and 7-valent pneumococcal conjugate [PCV7]) or routine infant vaccines alone. Toddlers received the fourth dose of MENVEO concomitantly with PCV7, measles, mumps, rubella, and varicella (MMRV), and inactivated hepatitis A vaccines.1
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.